Mineralys Therapeutics, Inc.
MLYS
$25.02
-$0.71-2.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.72% | 14.66% | -2.52% | 13.76% | 13.13% |
| Total Depreciation and Amortization | -13.33% | -6.25% | 6.67% | 0.00% | 36.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.74% | 48.24% | -10.58% | 44.63% | 320.84% |
| Change in Net Operating Assets | -246.61% | -57.27% | 282.77% | 70.12% | -444.68% |
| Cash from Operations | -31.23% | 4.30% | 33.68% | 31.95% | -33.19% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 31.25% | -250.99% | 53.83% | -211.14% | 4.93% |
| Cash from Investing | 31.24% | -250.99% | 53.83% | -211.14% | 4.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -67.14% | 2,888.63% | -94.78% | 138,067.15% | 242.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -951.72% | 38.30% | -370.00% | 78.72% | -14.63% |
| Cash from Financing | -67.24% | 2,902.62% | -94.81% | 210,210.00% | 9,100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.58% | 283.19% | -224.16% | 202.77% | -42.83% |